COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus (COMBAT)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 6, 2007
Last updated: November 30, 2010
Last verified: November 2010
To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Estimated Enrollment: 9000
Study Start Date: June 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary Care

Inclusion Criteria:

  1. Patients who have consented to participation/data release in this study
  2. Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision

Exclusion Criteria:

  1. Secondary hypertension requiring therapy other than antihypertensive medication
  2. Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
  3. Women in pregnancy or lactation
  4. Patients enrolled in any other studies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00526279

Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

No publications provided Identifier: NCT00526279     History of Changes
Other Study ID Numbers: NIS-CKR-ATA-2007/2
Study First Received: September 6, 2007
Last Updated: November 30, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:
Atacand/Atacand plus

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Candesartan cilexetil
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2015